log in | register
Username
Password
Remember me
Journals
Services
Search
Advanced search
Summary
August 2007, Vol. 8, No. 11, Pages 1733-1742
(doi:10.1517/14656566.8.11.1733)

Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage
James W Anderson
Endocrine Division, Department of Internal Medicine, College of Medicine, University of Kentucky, Room 524, Medical Science Building, Lexington KY 50536-0298, USA.



Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~ 25% of ingested fat and has ~ 85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss with diet and orlistat 60 mg averages ~ 5% of initial body weight. The 60-mg dose is better tolerated than the 120-mg dose and the gastrointestinal side effects are minimal when individuals consume < 30% of their energy from fat. In addition to facilitating modest weight loss, orlistat use decreases serum LDL-cholesterol values by ~ 10%. When taken three times daily before meals, orlistat 60 mg modifies lifestyle behavior, encourages lower fat-consumption and sets the stage for other healthy lifestyle changes.

Full Text PDF (202.631 KB) PDF Plus (283.486 KB)
 

Prev. Article | Next Article
View/Print PDF (203 KB)
View PDF Plus (283 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

Quick Links
 • Alert me when:
New articles cite this article
 • Download to citation manager
 • Related articles found in:
Expert Opinion series
 • View Most Downloaded Articles
 
 
Quick Search
for 
Author:
James W Anderson
Keywords:
cardiovascular disease risk
energy-restricted diets
lipase inhibitor
low-density-lipoprotein cholesterol
obesity
orlistat
weight loss
weight maintenance


Informa Healthcare, Telephone House, 69-77 Paul Street, London, EC2A 4LQ, UK
Tel: +44 (0)20 7017 5000 · Fax: +44 (0)20 7017 7667
We welcome your Feedback. See our Privacy Statement and Terms and Conditions